NCT03483974: HINED

Hyperspectral Imaging for Neoplasm Early Stage Detection

Status unknown Last updated 30 March 2018

What this trial tests

trial testing hyperspectral imaging in Hyperspectral Imaging Data of Excreta in 100 participants. Status unknown.

Timeline

1 August 2017

Primary endpoint
1 August 2018

30 September 2018

Quick facts

Lead sponsor	Chang Gung Memorial Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	100
Start date	1 August 2017
Primary completion	1 August 2018
Estimated completion	30 September 2018
Sites	1 location across Taiwan

Drugs / interventions tested

• hyperspectral imaging

Conditions studied

• Hyperspectral Imaging Data of Excreta — all drugs for Hyperspectral Imaging Data of Excreta →

Sponsor

Chang Gung Memorial Hospital

Who can join

20 and older, any sex, with Hyperspectral Imaging Data of Excreta. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background Information With the advance in cancer biology, we realize that malignant neoplasm is related with different biological patterns in metabolome and microbiota. Because of the progress in optical spectrometry, it has become possible to evaluate whole visible and innon-visiable absorptive spectrum in human specimens, which may enable detection of minor changes in compound related with altered metabolome and microbiota. We hope to utilize hyperspectral imagingthis spectrum technology to reveal the possible clues of neoplasm for early stage detection

Material and Methods This research intended to enroll one hundred patients into the study. This includes patients with positive stool or urine analysis admitted for workup of colorectal cancer. We will scan the stool and urine with hyperspectral imaging sensoroptical spectrometer, which utilize multichannel charge-coupled device and InGaAs array to analyze the full spectrum of light patterns. The image pattern will be stored and used to linked final diagnosis. Absorption, scattering, and reflection spectra are expected for analysis. Follow up analysis after cancer staging will be used for lowering background noise in all spectra.

Expected Results We expect that there will be specific spectral pattern in stool of colorectal cancer patients, which may be related with cancer staging and different from those in patients without malignancy. Difference in spectra will lead to discovery of new biomarker for colorectal cancer and related diseases. The optic spectra pattern of stool and urine may assist early diagnosis and staging of different malignancies

Publications & conference data

No peer-reviewed publications indexed yet for this trial.